<DOC>
<DOCNO>EP-0626367</DOCNO> 
<TEXT>
<INVENTION-TITLE>
(7S)-7-(1R)-2-(3-chlorophenyl)-2-hydroethylamino-5,6,7,8-tetrahydronaphtalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C21754	C07C21762	C07C21700	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07C	C07C	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C217	C07C217	C07C217	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to the new compound, {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino]-5,6,7,8-tetrahyd ro-2-naphthyloxy}acetic acid, of formula (I) 
<
IMAGE
>
 and to its pharmaceutically acceptable salts, possessing  beta 3-adrenergic agonist action, and to the pharmaceutical compositions and to the laboratory reagents containing it.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SANOFI SA
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI WINTHROP S P A
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI WINTHROP S.P.A.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BARONI MARCO
</INVENTOR-NAME>
<INVENTOR-NAME>
CECCHI ROBERTO
</INVENTOR-NAME>
<INVENTOR-NAME>
CROCI TIZIANO
</INVENTOR-NAME>
<INVENTOR-NAME>
BARONI, MARCO
</INVENTOR-NAME>
<INVENTOR-NAME>
CECCHI, ROBERTO
</INVENTOR-NAME>
<INVENTOR-NAME>
CROCI, TIZIANO
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
{(7S)-7-[(2R)-2-(3-Chlorophenyl)-2-hydroxyethylamino]-5,6,7,8-tetrahydronaphthalen-2-yloxy}acetic 

acid of formula (I): 

 
and its pharmaceutically acceptable salts. 
The sodium salt of the compound of claim 1. 
Use of the compound of claim 1 for the preparation 
of a drug intended for the treatment and prophylaxis 

of pathological conditions which can be improved 
by means of an agonistic action mediated by the receptors 

of the Î²
3
-adrenergic type. 
Use according to claim 3 for the preparation 
of a drug intended for the treatment and/or 

prophylaxis of gastrointestinal disorders due to contraction 
of the smooth muscle. 
Use according to claim 4 in the treatment and/or 
prophylaxis of irritable colon. 
Use according to claim 3 for the preparation of 
a drug intended for the treatment and/or prophylaxis of 

obesity. 
Use according to claim 3 for the preparation 
of a drug intended for the treatment and/or 

prophylaxis of depressive and anxio-depressive states 
and anxiety caused by stress. 
Use according to claim 3 for the preparation of 
a drug intended for the treatment and/or prophylaxis
 of 
eye complaints.  

 
A pharmaceutical composition in which the 
compound of claim 1 is present as the active principle. 
A pharmaceutical composition of claim 9 containing 
from 0.01 to 500 mg of active principle. 
A laboratory reagent in which a compound according 
to claim 1, either as such or labeled, is present 

as the active product. 
</CLAIMS>
</TEXT>
</DOC>
